Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
131I-TLX101 Plus Standard of Care in Patients With Newly Diagnosed Glioblastoma
NCT05450744Phase 1Active, not recruiting
- Sponsor
- Telix Pharmaceuticals Limited
- Start
- Apr 2023
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of 4-iodophenylalanine I-131 in glioblastoma (GBM), sponsored by Telix Pharmaceuticals Limited. Primary endpoints: Dose-Limiting Toxicities at 62 weeks and Safety, tolerability and Recommended Phase 2 Dose (RP2D) at 62 weeks. Started Apr 2023; status: active, not recruiting.
02
Drugs
4-iodophenylalanine I-131
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05450744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05450744.